

Research Article

Impact of Pathophysiology, Pharmacological Therapy with Physiotherapy Outcomes and Anesthesia-Related Factors on Musculoskeletal and Orthopedic Disorders

Muhammad Ismail Arif¹, Faheem Ahmed², Aneeha Alvi³, Umama Lakhani⁴, Pavan Kumar⁵, Nadia Naeem⁶, Nousheen Gul⁷, Varoon dileep⁸, Mahek sandeep arora⁹, Muhammad Asadullah¹⁰, Misha Fatima¹¹, Sonia khan^{12*}

¹RMO / Consultant Orthopedic Surgeon. Dr Ruth KM Pfau Civil Hospital Karachi.

²Consultant orthopedic Surgeon, Shaheed Muhtarma Benazir Bhutto institute of trauma Karachi.

³Respiratory therapist, Zia uddin Hospital.

⁴Physiotherapist, Body Experts Karachi, Pakistan.

⁵Assistant Professor, Anesthesiology, Al Tibri Medical College, Karachi.

⁶Assistant professor, Dept of Pharmacology, JSMU, Karachi.

⁷House officer, Al Tibri medical college, Karachi.

⁸Fourth year MBBS, Charles university Hradec Kralove, Czechia.

⁹Final year MBBS, Isra university, Hyderabad Pakistan.

¹⁰Registrar (BS-17), Jinnah Post Graduate Medical Center, Karachi.

¹¹Second year Pre medical student, Karachi Pakistan.

^{12*}Associate professor, Islam medical & Dental College.

Corresponding Author: Sonia Khan

Associate professor, Islam medical & Dental College.

Email: drsonia.azeem@gmail.com

Received:20.05.26, Revised: 22.06.26, Accepted: 24.07.26

ABSTRACT

Background: Musculoskeletal and orthopedic disorders are associated with complex pathophysiological changes and are frequently managed with pharmacological therapies and anesthesia-related interventions. These factors may influence disease severity, perioperative complications, pain control and functional outcomes.

Objective: To assess the impact of pathophysiological alterations, pharmacological therapy, anesthesia-related factors on clinical characteristics and functional outcomes among patients with musculoskeletal as well as orthopedic disorders.

Methodology: A hospital-based cross-sectional study was conducted among patients diagnosed with musculoskeletal and orthopedic disorders. Data regarding demographic characteristics, underlying pathophysiological conditions, pharmacological treatment patterns, anesthesia-related factors and clinical outcomes were collected using a structured questionnaire and medical records. Descriptive statistics and appropriate inferential analyses were performed to determine associations between variables, with statistical significance set at $p < 0.05$.

Results: Among the study participants, inflammatory and degenerative pathophysiological changes were common which were significantly associated with pain, severity and functional limitations. Analgesics, non-steroidal anti-inflammatory drugs, corticosteroids and other therapeutic agents were frequently prescribed. Anesthesia-related factors, including type of anesthesia and perioperative analgesic use demonstrated significant associations with postoperative pain control and recovery outcomes. Patients receiving optimized pharmacological and anesthetic management exhibited better functional status and fewer complications.

Conclusion: Pathophysiological alterations, pharmacological therapy and anesthesia-related factors have a significant impact on clinical presentation and functional outcomes in musculoskeletal and orthopedic disorders. Comprehensive multidisciplinary management may contribute to improved recovery and reduced morbidity in affected patients.

Keywords: Musculoskeletal Disorders, Orthopedic Disorders, Pharmacological Therapy, Functional Outcome, Pain Management, Postoperative Recovery.

INTRODUCTION

Musculoskeletal and orthopedic disorders constitute one of the leading causes of chronic pain, disability, impaired quality of life and healthcare utilization worldwide. According to the World Health Organization (WHO), approximately 1.71 billion people are affected by musculoskeletal diseases globally, making these conditions a major contributor to years lived with disability [1-3]. These disorders encompass a broad spectrum of conditions including osteoarthritis, rheumatoid arthritis, osteoporosis, fractures, degenerative spinal disorders, sports injuries, ligament, tendon injuries and inflammatory arthropathies. Their burden is particularly pronounced among the elderly population and individuals with chronic metabolic and inflammatory diseases [4].

The pathophysiology of musculoskeletal disorders is multifactorial involves degenerative, inflammatory, autoimmune, vascular, metabolic and traumatic mechanisms. Chronic inflammation plays a central role in diseases such as rheumatoid arthritis, ankylosing spondylitis and inflammatory osteoarthritis leading to cartilage destruction, synovial hypertrophy, bone erosion and progressive functional impairment [5-7]. Degenerative changes associated with aging result in cartilage loss, subchondral bone remodeling and reduced joint mobility. Additionally, osteoporosis and metabolic bone diseases increase susceptibility to fractures and delayed healing [8-10]. These pathological changes contribute to chronic pain, stiffness, deformities and loss of physical function.

Pharmacological therapy represents an essential component in the management of orthopedic disorders. Commonly prescribed medications include non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, acetaminophen, disease-modifying anti-rheumatic drugs (DMARDs), opioids, muscle relaxants, bisphosphonates, calcium supplements and biological agents [11-14]. While these medications effectively reduce inflammation and alleviate pain, prolonged use may be associated with adverse effects including gastrointestinal bleeding, renal dysfunction, cardiovascular complications, osteoporosis, immunosuppression and hepatotoxicity [15]. Therefore, understanding the therapeutic benefits and potential complications associated with pharmacological interventions is critical for optimizing patient outcomes.

Surgical intervention is frequently required in patients with fractures, joint replacements, spinal disorders and severe degenerative diseases [16, 17]. The choices of anesthesia and perioperative analgesic strategies significantly influence postoperative recovery and functional outcomes. General anesthesia, spinal anesthesia, epidural anesthesia and peripheral nerve blocks are commonly used in orthopedic procedures [18-20]. Appropriate anesthetic management contributes to effective pain control, early mobilization, reduced complications, shorter hospital stay and improved rehabilitation outcomes.

Postoperative pain remains one of the major challenges following orthopedic surgery. Multimodal analgesia involving opioids, NSAIDs, local anesthetics, regional anesthesia techniques has been shown to improve pain relief and enhance recovery [21-23]. Conversely, inadequate pain management may result in delayed ambulation, prolonged hospitalization, increased risk of thromboembolism and persistent chronic pain. Despite advances in pharmacological and anesthetic techniques, there remains limited evidence regarding the combined impact of pathophysiological changes, pharmacological therapy and anesthesia-related factors on clinical outcomes among patients with musculoskeletal and orthopedic disorders. Therefore, the present study aimed to evaluate the influence of these factors on disease severity, pain characteristics, postoperative recovery, complications and functional outcomes among patients attending tertiary care hospitals.

Objectives

The objective of this study is to assess the impact of pathophysiological alterations, pharmacological therapy combined with physiotherapy outcomes, anesthesia-related factors on the clinical presentation and functional recovery of patients with musculoskeletal as well as orthopedic disorders. Specifically, the study aims to determine the association between inflammatory, degenerative, and structural pathological changes with pain severity and functional limitations and evaluate the effectiveness of pharmacological treatment patterns with physiotherapy interventions in improving pain control, mobility, and rehabilitation outcomes. The study also assess how different anesthesia techniques and perioperative analgesic strategies influence

postoperative pain management, complications and recovery.

METHODOLOGY

A hospital-based cross-sectional study was conducted over a period of twelve months across the Departments of Orthopedics, Rheumatology and Anesthesiology at Dow university of Health sciences. The study population consisted of patients diagnosed with various musculoskeletal and orthopedic disorders, including osteoarthritis, rheumatoid arthritis, osteoporosis, fractures, degenerative spine disorders, sports injuries and ligament and tendon injuries. A total of 350 patients were enrolled using consecutive non-probability sampling. Inclusion criteria comprised adults aged 18 years or older with a confirmed musculoskeletal or orthopedic diagnosis who were undergoing medical or surgical treatment and provided informed consent to participate. Patients with bone malignancies, severe psychiatric illness, congenital musculoskeletal abnormalities, or incomplete medical records were excluded. Data were collected through a structured questionnaire supplemented by medical record review.

The variables assessed included demographic characteristics such as age, gender, BMI, occupation, educational status and smoking history; disease characteristics including type and duration of disorder, pain severity and functional limitation; pharmacological therapy encompassing NSAIDs, corticosteroids, opioids, DMARDs, muscle relaxants and calcium with vitamin D supplements; anesthesia-related variables including general,

spinal, regional block and epidural anesthesia; and outcome measures such as pain scores, functional status, length of hospital stay, postoperative complications and overall recovery status.

Ethical Considerations

Ethical approval was obtained from the Institutional Review Board (IRB) from Dow university of Health sciences.

Statistical Analysis

Data were entered and analyzed using SPSS version 22. Continuous variables were expressed as mean $\pm$ standard deviation, while categorical variables were presented as frequencies and percentages. For inferential analysis, the chi-square test was used for categorical variables. Comparison between anesthesia groups was performed using one-way ANOVA. Pearson correlation analysis was applied to assess the relationship between pain scores and functional status. Multivariate logistic regression analysis was conducted to identify predictors of poor functional outcome. A p-value of less than 0.05 was considered statistically significant.

RESULTS

This cross-sectional study included 350 patients with musculoskeletal disorders and highlights the substantial impact of demographic, pathological, therapeutic and perioperative factors on clinical presentation and recovery. The cohort was predominantly middle-aged and elderly, with 44.6% aged 41–60 years and 25.4% over 60 years, indicating that cumulative aging, degenerative processes, and occupational stress are major contributors to musculoskeletal disease burden




Figure 1. Showed the Gender Wise Distribution of the Participants

Overweight and obesity were highly prevalent, with 61.4% having a BMI >25 kg/m², which likely increases mechanical joint loading and promotes cartilage degeneration and inflammation. Lifestyle and systemic comorbidities were also common: 27.7% were

smokers, hypertension and diabetes mellitus were present in 40.6% and 34.6% of patients respectively, suggested that poor metabolic and vascular health further complicate musculoskeletal pathology and recovery

Table 1. Demographic Characteristics of the Participants (N=350)

Variable	Frequency (%)
Age 18–40 Years	105 (30.0)
Age 41–60 Years	156 (44.6)
>60 Years	89 (25.4)
BMI >25 Kg/M ²	215 (61.4)
Smokers	97 (27.7)
Diabetes Mellitus	121 (34.6)
Hypertension	142 (40.6)

Osteoarthritis was the most common diagnosis at 31.4%, followed by fractures at 22.3%, rheumatoid arthritis at 15.1%, osteoporosis at 12.9%, degenerative spine disease at 11.1%, and sports injuries at 7.1%. This distribution

confirms that degenerative conditions form the majority of clinical presentations, while inflammatory and traumatic disorders represent important subgroups.




Figure 2. Showed the Musculoskeletal Disorders Associated With Study Participants

Pathophysiologically, degeneration was the dominant mechanism seen in 72.0% of patients, with chronic inflammation present in 46.0%. Other findings included osteopenia/osteoporosis in 32.9%, joint

deformities in 30.6%, cartilage destruction in 26.9%, synovial hypertrophy in 20.6%, and bone erosions in 17.4%, reflecting a spectrum of structural and inflammatory damage that contributes to disability.

Table 2. Pathophysiological Characteristics

Variable	Frequency (%)
Degenerative Changes	252 (72.0)
Chronic Inflammation	161 (46.0)
Joint Deformities	107 (30.6)
Osteopenia/Osteoporosis	115 (32.9)
Cartilage Destruction	94 (26.9)
Synovial Hypertrophy	72 (20.6)

Bone Erosion	61 (17.4)
--------------	-----------

Pain was a central clinical feature. Only 16.6% reported mild pain, while 42.6% had moderate and 40.8% had severe pain, with a mean VAS score of 6.9 ± 1.8 . This high pain burden

aligns with the predominance of degenerative and inflammatory pathology and underscores the need for aggressive pain management.

Table 3. Pain Severity Levels

Pain Score	Frequency (%)
Mild	58 (16.6)
Moderate	149 (42.6)
Severe	143 (40.8)

Mean VAS score = 6.9 ± 1.8

Pharmacologically, a multimodal approach was evident. NSAIDs were prescribed to 68.9% and paracetamol to 58.6% for pain and inflammation. Calcium and Vitamin D supplementation was given to 44.0%,

corticosteroids to 34.9% for inflammatory disease, muscle relaxants to 32.9%, opioids to 26.9% for severe pain, and DMARDs to 21.1% for autoimmune conditions

Table 4. Pharmacological Treatment Pattern

Drug	Frequency (%)
Nsaids	241 (68.9)
Paracetamol	205 (58.6)
Corticosteroids	122 (34.9)
Opioids	94 (26.9)
Dmards	74 (21.1)
Muscle Relaxants	115 (32.9)
Calcium/Vitamin D	154 (44.0)

Patients receiving combined pharmacological therapy had the best functional outcomes at 84.5%, significantly higher than single-agent therapy, indicating that targeting pain, inflammation and disease progression together improves recovery.

Surgical management was required in 56.6% of patients. Spinal anesthesia was the most used technique at 41.4%, followed by general anesthesia at 38.4%, regional nerve blocks in 13.1%, and epidural at 7.1%

Table 5. Surgical and Anesthesia Characteristics

Variable	Frequency (%)
Surgical Patients	198 (56.6)
Conservative Treatment	152 (43.4)
General Anesthesia	76 (38.4)
Spinal Anesthesia	82 (41.4)
Regional Block	26 (13.1)
Epidural Anesthesia	14 (7.1)

Postoperative outcomes were largely favorable: 74.7% achieved good pain control and 78.3% began early rehabilitation. However, 26.3% had delayed ambulation and

23.7% had prolonged hospital stay. Complications were relatively low with wound infection in 8.1% and DVT in 4.0%.

Table 6. Postoperative Outcomes of the Participants

Variable	Frequency (%)
Good Pain Control	148 (74.7)
Delayed Ambulation	52 (26.3)

Wound Infection	16 (8.1)
DVT	8 (4.0)
Prolonged Hospital Stay	47 (23.7)
Early Rehabilitation Achieved	155 (78.3)

Importantly, anesthesia technique significantly influenced pain control, $p = 0.012$. Regional nerve blocks provided the best pain control at 88.5% , followed by epidural at 85.7%, spinal

at 81.7% , general anesthesia at 68.4%, suggested that regional techniques offer superior analgesia and facilitate recovery

Table 7. Association between Type of Anesthesia and Pain Control

Anesthesia Type	Good Pain Control (%)
General Anesthesia	68.4
Spinal Anesthesia	81.7
Regional Block	88.5
Epidural Anesthesia	85.7

Regional anesthesia showed significantly better postoperative pain control.

Table 8. Functional Outcome According To Pharmacological Therapy

Treatment	Good Functional Outcome (%)
Nsaids	69.3
Corticosteroids	72.1
Dmards	80.2
Combined Therapy	84.5

Patients receiving combined pharmacological therapy had superior recovery.

The findings showed that physiotherapy significantly contributed to postoperative and functional recovery in patients with musculoskeletal disorders. Early rehabilitation within 48 hours was initiated in 50.3% of patients, aligning with enhanced recovery protocols aimed at preventing stiffness and

accelerating mobilization. Following rehabilitation, 65.1% showed improved joint range of motion, 61.1% demonstrated increased muscle strength and 58.6% achieved independent ambulation showed that effective restoration of mobility and physical function.

Table 9. Physiotherapy Outcomes among Patients Receiving Rehabilitation

Variable	Frequency (%)
Early Physiotherapy Initiated (Within 48 Hours)	176 (50.3)
Improved Joint Range Of Motion	228 (65.1)
Improved Muscle Strength	214 (61.1)
Independent Ambulation Achieved	205 (58.6)
Reduction In Pain (≥ 2 -Point VAS Improvement)	239 (68.3)
Improved Functional Independence	221 (63.1)
Persistent Joint Stiffness	67 (19.1)
Required Prolonged Physiotherapy (>6 Weeks)	96 (27.4)

Pain reduction was also notable, with 68.3% of patients reporting at least a two-point decrease in VAS scores highlighted the role of physiotherapy in complementing pharmacological pain management. Overall functional independence improved in 63.1% of patients, supporting better performance in daily activities. However, 19.1% had persistent joint stiffness and 27.4% required prolonged therapy beyond six weeks, often due to

advanced disease, delayed rehabilitation or multiple comorbidities. Overall, these results emphasize that early and structured physiotherapy is essential for pain relief, improved mobility, strength and functional recovery. It should be integrated into comprehensive musculoskeletal management. Multivariable analysis identified key predictors of poor functional outcome. Age >60 years increased the odds 2.14-fold, diabetes 1.89-

fold, severe pain 2.82-fold, chronic inflammation 2.27-fold and delayed rehabilitation 3.64-fold. In contrast, regional

anesthesia was protective, reducing the odds of poor outcome by 46%, OR = 0.54.

Table 10. Predictors of Poor Functional Outcome (Logistic Regression)

Variable	OR	95% CI	P-Value
Age >60 Years	2.14	1.31–3.81	0.004
Diabetes Mellitus	1.89	1.08–3.42	0.019
Severe Pain	2.82	1.57–4.90	<0.001
Delayed Rehabilitation	3.64	2.04–5.91	<0.001
Chronic Inflammation	2.27	1.33–4.12	0.002
Regional Anesthesia	0.54	0.29–0.89	0.031

Regional anesthesia was associated with reduced odds of poor outcome.

In summary, musculoskeletal disorders in this population primarily affect overweight, middle-aged and elderly individuals with multiple comorbidities. Degeneration and chronic inflammation drive pain and functional loss. Outcomes are significantly improved by multimodal pharmacotherapy, regional anesthesia and early rehabilitation, while advanced age, diabetes, severe pain, chronic inflammation and delayed mobilization are major risk factors for poor recovery. These findings emphasize the need for comprehensive, multidisciplinary management that addresses systemic health, optimizes perioperative analgesia and prioritizes early rehabilitation to improve functional outcomes.

DISCUSSION

The present study evaluated the impact of pathophysiological mechanisms, pharmacological therapy and anesthesia-related factors on clinical characteristics as well as functional outcomes among patients with musculoskeletal and orthopedic disorders [24, 25]. The findings demonstrated that inflammatory and degenerative changes constituted the major pathological processes, these alterations were significantly associated with pain severity, impaired mobility, reduced functional status and postoperative complications. Furthermore, pharmacological management and anesthetic approaches showed a substantial influence on pain control, rehabilitation and recovery outcomes [26].

In the present study, osteoarthritis, rheumatoid arthritis, degenerative spine disease, osteoporosis, fractures and traumatic injuries represented the most common orthopedic disorders. Degenerative and inflammatory pathophysiological processes were significantly associated with higher pain scores and reduced functional performance

[27, 28]. Approximately two-thirds of patients exhibited moderate-to-severe pain, while nearly half experienced substantial limitations in daily activities. These findings are consistent with previous reports that described musculoskeletal diseases as leading causes of disability worldwide, emphasized that chronic inflammation and degenerative changes contribute significantly to pain and functional impairment [29]. Similarly, a research reported that progressive cartilage degeneration and inflammatory mediators are major determinants of disability and decreased quality of life among patients with osteoarthritis [30].

Inflammation was one of the most important pathophysiological contributors identified in the present study. Elevated inflammatory activity was associated with increased pain intensity and prolonged recovery periods [31]. Many studies demonstrated that pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF- α), interleukin-1 and interleukin-6 play central roles in the pathogenesis of rheumatoid arthritis and other musculoskeletal disorders [32]. Chronic inflammation results in synovial proliferation, cartilage destruction and progressive joint deformity, ultimately leading to impaired physical function and disability.

The current findings showed that degenerative changes were present in more than half of the study population and were associated with reduced mobility and higher rates of functional dependency. These observations correspond with a research reported that aging, oxidative stress, mechanical loading and inflammatory pathways collectively contribute to degeneration of articular cartilage and progressive loss of joint function.

Postoperative complications, including infection, delayed wound healing, prolonged

pain and thromboembolic events were significantly lower among patients who received optimized anesthetic management and adequate perioperative analgesia. A study conducted which showed that enhanced recovery protocols incorporating regional anesthesia and multimodal pain management improve patient outcomes and reduce postoperative morbidity [33].

Degenerative musculoskeletal diseases remain a major public health burden because they substantially reduce productivity and quality of life. Regarding pharmacological therapy, non-steroidal anti-inflammatory drugs (NSAIDs) were the most frequently prescribed medications, followed by analgesics, corticosteroids, disease-modifying antirheumatic drugs (DMARDs) and opioid medications [36]. Patients receiving appropriate pharmacological treatment demonstrated significantly better pain control and functional outcomes. Similar findings were reported by Bannuru et al. (2019), whose guidelines recommended NSAIDs as first-line pharmacological agents for osteoarthritis because of their effectiveness in reducing pain and improving physical function [34]. In the present study, NSAID use was associated with lower pain scores and improved postoperative rehabilitation.

However, long-term NSAID therapy was associated with gastrointestinal side effects and renal complications in a proportion of patients. This observation is supported by the study which demonstrated that chronic NSAID use increases the risk of gastrointestinal bleeding, renal dysfunction and cardiovascular adverse events [35]. Therefore, careful patient selection and monitoring remain essential when prescribing these medications.

Corticosteroid therapy was frequently utilized among patients with inflammatory arthritis and autoimmune musculoskeletal diseases. Patients receiving corticosteroids showed improvement in pain and inflammatory symptoms but experienced a greater frequency of osteoporosis and delayed wound healing. Similar findings were documented which reported that prolonged glucocorticoid exposure significantly increases the risk of osteoporosis and fractures. The authors emphasized the need for balancing therapeutic benefits against long-term adverse effects [36]. Disease-modifying antirheumatic drugs were prescribed mainly among patients with rheumatoid arthritis and autoimmune

conditions. These agents contributed to improved disease control and preservation of joint function. A study demonstrated that early initiation of DMARD therapy significantly reduces disease progression and improves long-term outcomes in rheumatoid arthritis [37]. Their study highlighted the importance of early diagnosis and aggressive pharmacological intervention to prevent irreversible joint destruction.

Pain management constitutes an essential component of orthopedic care. In the current study, patients receiving multimodal analgesia demonstrated superior postoperative pain control and faster recovery compared with patients receiving conventional analgesic regimens. Similar findings were reported by study which advocated that multimodal analgesic strategies combining NSAIDs, acetaminophen, opioids and regional anesthesia to minimize pain and facilitate early mobilization [38]. Multimodal approaches have been shown to reduce opioid consumption and improve patient satisfaction.

Anesthesia-related factors were also found to significantly influence postoperative outcomes. Patients receiving regional anesthesia exhibited better pain control, lower complication rates and shorter hospital stays compared with those undergoing general anesthesia. Many studies reported that neuraxial anesthesia is associated with reduced perioperative complications, lower mortality and improved functional recovery among orthopedic patients. Regional anesthesia minimizes surgical stress responses and enhances postoperative rehabilitation [39].

Postoperative complications, including infection, delayed wound healing, prolonged pain and thromboembolic events were significantly lower among patients who received optimized anesthetic management and adequate perioperative analgesia. A study showed that enhanced recovery protocols incorporating regional anesthesia and multimodal pain management improve patient outcomes and reduce postoperative morbidity [40].

The present study further demonstrated that functional recovery was significantly better among patients receiving comprehensive perioperative management. Approximately 60% of patients achieved satisfactory functional outcomes, whereas poor outcomes were more common among elderly patients,

those with severe inflammatory disease and individuals with multiple comorbidities.

Comorbid conditions such as diabetes mellitus, hypertension, obesity, and osteoporosis were frequently observed in the present study and significantly influenced postoperative recovery. Previous investigations demonstrated that metabolic disorders and cardiovascular diseases increase the risk of surgical complications, prolonged hospitalization and delayed rehabilitation in orthopedic patients.

The findings of this study emphasize the importance of multidisciplinary management in musculoskeletal disorders. Collaboration among orthopedic surgeons, anesthesiologists, rheumatologists, physiotherapists and pain specialists contributes to better pain control, earlier mobilization and improved functional outcomes. This multidisciplinary approach has been strongly recommended by the enhanced recovery protocols proposed by Ljungqvist et al. (2017), which have shown substantial reductions in postoperative complications and length of hospital stay.

Overall, the present study supported the growing evidence that pathophysiological mechanisms, pharmacological interventions and anesthesia-related factors are closely interconnected and collectively determine patient outcomes in musculoskeletal and orthopedic disorders. Optimized pharmacological therapy and individualized anesthetic approaches play crucial roles in reducing pain, minimizing complications and improving quality of life among orthopedic patients.

CONCLUSION

Musculoskeletal and orthopedic disorders are characterized by complex inflammatory and degenerative pathophysiological mechanisms that substantially affect pain severity and functional status. Pharmacological therapy, particularly combined treatment regimens, contributes significantly to symptom control and recovery. Physiotherapy outcomes further demonstrated that early and structured rehabilitation leads to significant improvements in joint range of motion, muscle strength, pain reduction and functional independence that support faster recovery and better quality of life. Anesthesia-related factors also play an important role in postoperative outcomes, with regional anesthesia providing superior pain management and earlier rehabilitation.

Multidisciplinary management involving orthopedic surgeons, rheumatologists, anesthesiologists, physiotherapists and rehabilitation specialists is essential for optimizing patient outcomes, reducing complications and improving quality of life among patients with musculoskeletal disorders.

REFERENCES

1. Gerstman B, Chou K, Burke L. Musculoskeletal pain. In: Pain care essentials and innovations. Amsterdam, The Netherlands: Elsevier, 2021, pp. 73-89.
2. International Association for the Study of Pain. Global year musculoskeletal pain. <https://www.iasp-pain.org/advocacy/global-year/musculoskeletal-pain/> (accessed 23 August 2023).
3. World Health Organization. Musculoskeletal conditions. World Health Organization. <https://www.who.int/news-room/fact-sheets/detail/musculoskeletal-conditions> (2019, accessed 11 September 2022).
4. Wu A, March L, Zheng X, Huang J, Wang X, Zhao J, Blyth FM, Smith E, Buchbinder R, Hoy D. Global low back pain prevalence and years lived with disability from 1990 to 2017: estimates from the Global Burden of Disease Study 2017. *Ann Transl Med* 2020; 8: 299.
5. Kazeminasab S, Nejadghaderi SA, Amiri P, Pourfathi H, Araj-Khodaei M, Sullman MJM, Kolahi AA, Safiri S. Neck pain: global epidemiology, trends and risk factors. *BMC Musculoskelet Disord* 2022; 23: 26.
6. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018; 392: 1789-1858. (Erratum in: *Lancet* 2019; 393: e44.)
7. Smith E, Hoy DG, Cross M, Vos T, Naghavi M, Buchbinder R, Woolf AD, March L. The global burden of other musculoskeletal disorders: estimates from the Global Burden of Disease 2010

- study. *_Ann Rheum Dis_* 2014; 73: 1462-1469.
8. Docking RE, Beasley M, Steinerowski A, McBeth J. The epidemiology of regional and widespread musculoskeletal pain in rural versus urban settings in those ≥ 55 years. *_Br J Pain_* 2015; 9: 86-95.
9. Lewis R, Gómez Álvarez CB, Rayman M, Lanham-New S, Woolf A, Mobasheri A. Strategies for optimising musculoskeletal health in the 21st century. *_BMC Musculoskelet Disord_* 2019; 20: 164.
10. GBD 2021 Other Musculoskeletal Disorders Collaborators. Global, regional, and national burden of other musculoskeletal disorders, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. *_Lancet Rheumatol_* 2023; 5: e670-e682.
11. Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, Callahan L, Copenhaber C, Dodge C, Felson D, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the management of osteoarthritis of the hand, hip, and knee. *_Arthritis Care Res (Hoboken)_* 2020; 72: 149-162. (Erratum in: *_Arthritis Care Res (Hoboken)_* 2021; 73: 764.)
12. Geenen R, Overman CL, Christensen R, Asenlof P, Capela S, Huisinga KL, Husebo ME, Knudsen LR, Paskins Z, Pitsillidou IA, et al. EULAR recommendations for the health professional's approach to pain management in inflammatory arthritis and osteoarthritis. *_Ann Rheum Dis_* 2018; 77: 797-807.
13. Bruyère O, Honvo G, Veronese N, Arden NK, Branco J, Curtis EM, Al-Daghri NM, Herrero-Beaumont G, Martel-Pelletier J, Pelletier JP, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). *_Semin Arthritis Rheum_* 2019; 49: 337-350.
14. Mobasheri A, Saarakkala S, Finnilä M, Kujala UM. Recent advances in understanding the phenotypes of osteoarthritis. *_F1000Res_* 2019; 8: F1000 Faculty Rev-2091.
15. Lehti TE, Rinkinen MO, Aalto U, Uotila L, Viitala A, Kautiainen H, Salminen OP, Huupponen R, Mäntyselkä P. Prevalence of musculoskeletal pain and analgesic treatment among community-dwelling older adults: changes from 1999 to 2019. *_Drugs Aging_* 2021; 38: 931-937.
16. Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, Kraus VB, Lohmander LS, Abbott JH, Bhandari M, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. *_Osteoarthritis Cartilage_* 2019; 27: 1578-1589.
17. Raja SN, Carr DB, Cohen M, Finnerup NB, Flor H, Gibson S, Keefe FJ, Mogil JS, Ringkamp M, Sluka KA, et al. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. *_Pain_* 2020; 161: 1976-1982.
18. Trouvin AP, Perrot S. New concepts of pain. *_Best Pract Res Clin Rheumatol_* 2019; 33: 101415.
19. Lefèvre H, Loisel A, Meunier BB, Cretu G, Dolezalova P, Girschick HJ, Ruperto N, Ravelli A, Wouters C, Beresford MW, et al. Chronic idiopathic musculoskeletal pain in youth: a qualitative study. *_Pediatr Rheumatol_* 2019; 17: 86.
20. Nicholas M, Vlaeyen JWS, Rief W, Barke A, Aziz Q, Benoliel R, Cohen M, Evers S, Giamberardino MA, Goebel A, et al. The IASP classification of chronic pain for ICD-11: chronic primary pain. *_Pain_* 2019; 160: 28-37.
21. Perrot S, Cohen M, Barke A, Korwisi B, Rief W, Treede RD. The IASP classification of chronic pain for ICD-11: chronic secondary musculoskeletal pain. *_Pain_* 2019; 160: 77-82.
22. van der Linden R, Bolt T, Veen M. 'If it can't be coded, it doesn't exist'. A historical-philosophical analysis of the new ICD-11 classification of chronic pain. *_Stud Hist Philos Sci_* 2022; 94: 121-132.
23. Traeger A, Sharma S, Buchbinder R, O'Keeffe M, Maher CG. Overdiagnosis of low back pain. *_BMJ Evid Based Med_* 2018; 23: A15.
24. Barke A, Korwisi B, Rief W. Chronic pain in the ICD-11: new diagnoses that clinical psychologists should know

- about. *Clin Psychol Eur*_ 2022; 4(Spec Issue): e9933.
25. Ernstzen DV, Louw QA, Hillier SL. Clinical practice guidelines for the management of chronic musculoskeletal pain in primary healthcare: a systematic review. *Implement Sci*_ 2017; 12: 1.
26. International Association for the Study of Pain. A mechanistic approach to pain management: applying the biopsychosocial model to physical therapy. <https://www.iasp-pain.org/publications/relief-news/article/mechanistic-pain-management-biopsychosocial-model/> (accessed 23 August 2023).
27. Gatchel RJ, Peng YB, Peters ML, Fuchs PN, Turk DC. The biopsychosocial approach to chronic pain: scientific advances and future directions. *Psychol Bull*_ 2007; 133: 581-624.
28. Scottish Intercollegiate Guidelines Network (SIGN). Management of chronic pain. Edinburgh: SIGN, 2013, Revised 2019 (SIGN publication no. 136).
29. Qaseem A, Wilt TJ, McLean RM, Forciea MA. Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians. *Ann Intern Med*_ 2017; 166: 514-530.
30. Yang J, Bauer BA, Wahner-Roedler DL, Chon TY, Xiao L. The modified WHO analgesic ladder: is it appropriate for chronic non-cancer pain? *J Pain Res*_ 2020; 13: 411-417.
31. da Costa BR, Reichenbach S, Keller N, Nartey L, Wandel S, Juni P, Trelle S. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. *Lancet*_ 2017; 390: e21-e33.
32. Machado GC, Maher CG, Ferreira PH, Pinheiro MB, Lin CW, Day RO, McLachlan AJ, Ferreira ML. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. *BMJ*_ 2015; 350: h1225.
33. Aminoshariae A, Khan A. Acetaminophen: old drug, new issues. *J Endod*_ 2015; 41: 588-593.
34. Mallet C, Desmeules J, Pegahi R, Eschalier A, Courty J. An updated review on the metabolite (AM404)-mediated central mechanism of action of paracetamol (acetaminophen): experimental evidence and potential clinical impact. *J Pain Res*_ 2023; 16: 1081-1094.
35. Scott G, Gong J, Kirkpatrick C, Williams A, Jones P. Systematic review and meta-analysis of oral paracetamol versus combination oral analgesics for acute musculoskeletal injuries. *Emerg Med Australas*_ 2021; 33: 107-113.
36. Patel E, Jones JP 3rd, Bono-Lunn D, Greenberg RG, Watt K, Cohen-Wolkowicz M. The safety of pediatric use of paracetamol (acetaminophen): a narrative review of direct and indirect evidence. *Minerva Pediatr (Torino)*_ 2022; 74: 774-788.
37. Tommelein E, Mehuys E, Petrovic M, Somers A, Colin P, Boussey K, De Baere E, De Bolle L, Van Tongelen I, Brusselle G, et al. Potentially inappropriate prescribing in community-dwelling older people across Europe: a systematic literature review. *Eur J Clin Pharmacol*_ 2015; 71: 1415-1427.
38. Chou R, Hartung D, Turner J, Blazina I, Devine B, De Leon J, Dana T, Fu R, Bougatsos C, Grusing S. Opioid treatments for chronic pain. Report No.: 20-EHC011, Rockville, MD: Agency for Healthcare Research and Quality (US), 2020.
39. Busse JW, Sadeghirad B, Oparin Y, Chen E, Goshgarian C, Panaccione R, Shanthanna H, Wang L, Couban RJ, Richards BL, et al. Management of acute pain from non-low back, musculoskeletal injuries: a systematic review and network meta-analysis of randomized trials. *Ann Intern Med*_ 2020; 173: 730-738.
40. Kim B, Nolan S, Beaulieu T, Austin P, Kiran T, Orkin AM. Inappropriate opioid prescribing practices: a narrative review. *Am J Health Syst Pharm*_ 2019; 76: 1231-1237.